Home›Cabozantinib›Cabozantinib + Lamivudine Oral

Does Cabozantinib Interact with Lamivudine Oral?

CDI records a moderate classification for Cabozantinib and Lamivudine Oral. The stored summary is: MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use. The mechanism involves mrp2 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Lamivudine Oral Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

MRP2 inhibition

What To Tell Your Doctor or Pharmacist

If you are taking Cabozantinib and your doctor is considering prescribing Lamivudine Oral (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Cabozantinib(Cometriq)+💊 Lamivudine Oral(Lamivudine)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Source
NLP:cabozantinib

What this means in plain English

MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.

About Cabozantinib and Lamivudine Oral

Lamivudine Oral is a Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor. Cabozantinib is also sold under the brand name Cometriq. Lamivudine Oral additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:cabozantinib

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Cabozantinib and Lamivudine Oral against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations